<DOC>
	<DOCNO>NCT00025090</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell . It yet know fluorouracil plus radiation therapy effective without additional chemotherapy treat anal cancer . PURPOSE : Randomized phase III trial compare effectiveness fluorouracil plus radiation therapy without additional chemotherapy treat patient primary anal cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Fluorouracil With Without Additional Chemotherapy Treating Patients With Primary Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate patient primary epidermoid anal cancer treat radiotherapy fluorouracil either mitomycin cisplatin without maintenance therapy . - Compare local control prevention delay disease dissemination patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients randomize one four treatment arm . All patient undergo radiotherapy daily 5 day week 5.5 week . All patient also receive fluorouracil IV continuously day 1-4 29-32 . - Arm I : Patients receive mitomycin IV day 1 . - Arm II : Patients receive cisplatin IV day 1 29 . - Arm III : Patients receive mitomycin arm I maintenance therapy comprise fluorouracil IV continuously day 1-4 cisplatin IV day 1 begin 4-8 week completion primary therapy repeat 3 week later . - Arm IV : Patients receive cisplatin arm II maintenance therapy arm III . Patients follow 2 month , every 3 month 2 year , every 6 month 3 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 600 patient ( 150 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary epidermoid anal cancer Squamous cell Basaloid Cloacogenic No adenocarcinoma , malignant melanoma , mucoepidermoid carcinoma , lymphoma , microinvasive anal intraepithelial neoplasia ( without evidence invasive disease ) anal canal margin No metastatic disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Liver function test great 2 time normal Renal : Glomerular filtration rate least 50 mL/min Cardiovascular : No cardiovascular disease No uncontrolled angina pectoris No heart failure No clinically significant cardiac arrhythmia Other : HIV negative No significant concurrent illness Not predominately bedbound frail No severe sepsis No prior concurrent cancer illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis Surgery : Not specify Other : No prior therapy anal cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage I anal cancer</keyword>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>cloacogenic carcinoma anus</keyword>
	<keyword>basaloid carcinoma anus</keyword>
</DOC>